Cargando…

Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B

BACKGROUND: The aim of this study was to investigate the variation of platelet-activating factor acetylhydrolase (PAF-AH) in patients with various stages of hepatitis B infection and evaluate the association between PAF-AH activity and chronic severe hepatitis B (CSHB) and mortality in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Limin, Zhao, Ying, Feng, Guofang, Chen, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096520/
https://www.ncbi.nlm.nih.gov/pubmed/24973921
http://dx.doi.org/10.1186/1476-511X-13-105
_version_ 1782326150801915904
author Feng, Limin
Zhao, Ying
Feng, Guofang
Chen, Yu
author_facet Feng, Limin
Zhao, Ying
Feng, Guofang
Chen, Yu
author_sort Feng, Limin
collection PubMed
description BACKGROUND: The aim of this study was to investigate the variation of platelet-activating factor acetylhydrolase (PAF-AH) in patients with various stages of hepatitis B infection and evaluate the association between PAF-AH activity and chronic severe hepatitis B (CSHB) and mortality in patients with hepatitis B. METHODS: Serum PAF-AH activity was measured in 216 patients with hepatitis B and in 152 healthy controls using an automatic biochemical analysis system. Spearman correlation was used to investigate the correlation between PAF-AH activity and other biochemical indicators. The receiver operating characteristic (ROC) curve and multivariable logistic regression analysis were used to evaluate the ability of PAF-AH activity to predict CSHB and mortality in patients with hepatitis B. RESULTS: The PAF-AH activities in patients with CSHB (1320 ± 481 U/L) were significantly higher than those in healthy controls and in other hepatitis B groups (all P < 0.01). In patients with hepatitis B, PAF-AH activity correlated with total bilirubin (r = 0.633), total bile acid (r = 0.559), aspartate aminotransferase (r = 0.332), apolipoprotein B (r = 0.348), high-density lipoprotein cholesterol (r = −0.493), and apolipoprotein AI (r = −0.530). The areas under the ROC curves for the ability of PAF-AH activity to predict CSHB and mortality in patients with hepatitis B were 0.881 (95% confidence interval (CI): 0.824–0.937, P < 0.001) and 0.757 (95% CI: 0.677–0.837, P < 0.001), respectively. Multivariate logistic regression analysis showed PAF-AH activity to be an independent factor predicting CSHB with an odds ratio of 1.003 (95% CI: 1.002–1.005, P < 0.001). CONCLUSION: Elevated PAF-AH in patients with hepatitis B was significantly associated with liver damage. Thus, serum PAF-AH could be used as a novel indicator for predicting CSHB and mortality in patients with hepatitis B. Further, PAF-AH activity was an independent factor predicting CSHB.
format Online
Article
Text
id pubmed-4096520
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40965202014-07-15 Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B Feng, Limin Zhao, Ying Feng, Guofang Chen, Yu Lipids Health Dis Research BACKGROUND: The aim of this study was to investigate the variation of platelet-activating factor acetylhydrolase (PAF-AH) in patients with various stages of hepatitis B infection and evaluate the association between PAF-AH activity and chronic severe hepatitis B (CSHB) and mortality in patients with hepatitis B. METHODS: Serum PAF-AH activity was measured in 216 patients with hepatitis B and in 152 healthy controls using an automatic biochemical analysis system. Spearman correlation was used to investigate the correlation between PAF-AH activity and other biochemical indicators. The receiver operating characteristic (ROC) curve and multivariable logistic regression analysis were used to evaluate the ability of PAF-AH activity to predict CSHB and mortality in patients with hepatitis B. RESULTS: The PAF-AH activities in patients with CSHB (1320 ± 481 U/L) were significantly higher than those in healthy controls and in other hepatitis B groups (all P < 0.01). In patients with hepatitis B, PAF-AH activity correlated with total bilirubin (r = 0.633), total bile acid (r = 0.559), aspartate aminotransferase (r = 0.332), apolipoprotein B (r = 0.348), high-density lipoprotein cholesterol (r = −0.493), and apolipoprotein AI (r = −0.530). The areas under the ROC curves for the ability of PAF-AH activity to predict CSHB and mortality in patients with hepatitis B were 0.881 (95% confidence interval (CI): 0.824–0.937, P < 0.001) and 0.757 (95% CI: 0.677–0.837, P < 0.001), respectively. Multivariate logistic regression analysis showed PAF-AH activity to be an independent factor predicting CSHB with an odds ratio of 1.003 (95% CI: 1.002–1.005, P < 0.001). CONCLUSION: Elevated PAF-AH in patients with hepatitis B was significantly associated with liver damage. Thus, serum PAF-AH could be used as a novel indicator for predicting CSHB and mortality in patients with hepatitis B. Further, PAF-AH activity was an independent factor predicting CSHB. BioMed Central 2014-06-28 /pmc/articles/PMC4096520/ /pubmed/24973921 http://dx.doi.org/10.1186/1476-511X-13-105 Text en Copyright © 2014 Feng et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Feng, Limin
Zhao, Ying
Feng, Guofang
Chen, Yu
Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B
title Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B
title_full Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B
title_fullStr Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B
title_full_unstemmed Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B
title_short Clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis B
title_sort clinical application of elevated platelet-activating factor acetylhydrolase in patients with hepatitis b
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096520/
https://www.ncbi.nlm.nih.gov/pubmed/24973921
http://dx.doi.org/10.1186/1476-511X-13-105
work_keys_str_mv AT fenglimin clinicalapplicationofelevatedplateletactivatingfactoracetylhydrolaseinpatientswithhepatitisb
AT zhaoying clinicalapplicationofelevatedplateletactivatingfactoracetylhydrolaseinpatientswithhepatitisb
AT fengguofang clinicalapplicationofelevatedplateletactivatingfactoracetylhydrolaseinpatientswithhepatitisb
AT chenyu clinicalapplicationofelevatedplateletactivatingfactoracetylhydrolaseinpatientswithhepatitisb